৳ 690.67/unit
Pack: ৳ 82,880.40
৳ 690.67/unit
Pack: ৳ 82,880.40
At a glance
ALK and RET tyrosine kinase inhibitor indicated for ALK-positive advanced non-small cell lung cancer (NSCLC).
Indications
Indicated as monotherapy for first-line treatment or for patients with ALK-positive advanced NSCLC previously treated with crizotinib.
Pharmacology
Alectinib blocks ALK tyrosine kinase activity and downstream STAT3 and PI3K/AKT pathways, triggering apoptosis in tumor cells. It crosses the blood-brain barrier to target CNS metastases.
Dosage
Recommended Dose: 600 mg (four 150 mg capsules) twice daily with food. Severe hepatic impairment (Child-Pugh C): 450 mg twice daily with food. Dose reductions in steps of 150 mg BD for toxicity.
Side effects
Constipation, edema, myalgia, nausea, increased bilirubin, anemia, and rash.
Use in pregnancy
May cause fetal harm. Effective contraception required during treatment and for at least 3 months after the last dose.
Pregnancy Category: D — always consult a doctor before taking during pregnancy.
Precautions & warnings
Monitor for Interstitial Lung Disease (ILD)/pneumonitis, hepatotoxicity, symptomatic bradycardia, and photosensitivity (use SPF >50 sunscreen). Avoid during pregnancy.
Overdose effects
No specific antidote. Provide general supportive care and monitoring.
Storage conditions
Store below 30°C in a dry place away from light and moisture. Keep out of reach of children.